The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. In a recent update, Eli Lilly and Company announced the ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Dubbed the ‘guardian of the genome’, the p53 protein responds to DNA damage by stalling cell division, initiating DNA repair ...